Suppr超能文献

新型强心剂MCI - 154与某些钙敏化剂对去表皮心肌收缩系统对钙离子反应影响的比较

Comparison of the effects of MCI-154, a new cardiotonic agent, and some Ca2+-sensitizing agents on the response of the contractile system to Ca2+ in skinned cardiac muscle.

作者信息

Kitada Y, Morita M, Narimatsu A

机构信息

Pharmaceuticals Laboratory, Mitsubishi Kasei Corporation, Yokohama, Japan.

出版信息

Jpn J Pharmacol. 1989 Aug;50(4):411-9. doi: 10.1254/jjp.50.411.

Abstract

Several cardiotonic agents (MCI-154, sulmazole, pimobendan and adibendan) were examined for their ability to influence Ca2+-activated tension development and MgATP-activated tension development in the absence of free Ca2+ (rigor tension), using the chemically skinned fiber from guinea pig papillary muscles. MCI-154, sulmazole, pimobendan and adibendan all increased the tension development induced by pCa (-log[Ca2+]M) 5.8 in a concentration-dependent manner (10(-6) to 10(-4) M). The order of the potency was as follows: MCI-154 greater than pimobendan greater than adibendan greater than sulmazole. MCI-154 enhanced the maximum tension developed at pCa 4.4 but sulmazole, pimobendan and adibendan did not enhance it. MCI-154, but not sulmazole, pimobendan and adibendan, enhanced the tension development induced by pMgATP (-log[MgATP]M) 6.0 in the absence of free Ca2+. MCI-154, sulmazole, pimobendan and adibendan concentration-dependently (10(-7) to 10(-4) M) increased the force of contraction in isolated guinea pig papillary muscles. The order of the potency was as follows: MCI-154 greater than adibendan greater than pimobendan greater than sulmazole. These results demonstrated that the Ca2+-sensitizing action on the contractile system may be involved in the positive inotropic action of MCI-154, sulmazole, pimobendan and adibendan, and that MCI-154 is the most potent among these drugs. Furthermore, sulmazole, pimobendan and adibendan did not enhance the interaction of actin and myosin, suggesting that the mechanism of actions of these drugs are qualitatively different from that of MCI-154.

摘要

使用豚鼠乳头肌的化学去表皮纤维,研究了几种强心剂(MCI-154、舒马唑、匹莫苯丹和阿迪苯丹)在无游离Ca2+(强直张力)情况下影响Ca2+激活的张力发展和MgATP激活的张力发展的能力。MCI-154、舒马唑、匹莫苯丹和阿迪苯丹均以浓度依赖性方式(10(-6)至10(-4)M)增加了由pCa(-log[Ca2+]M)5.8诱导的张力发展。效力顺序如下:MCI-154>匹莫苯丹>阿迪苯丹>舒马唑。MCI-154增强了在pCa 4.4时产生的最大张力,但舒马唑、匹莫苯丹和阿迪苯丹没有增强。MCI-154而非舒马唑、匹莫苯丹和阿迪苯丹增强了在无游离Ca2+情况下由pMgATP(-log[MgATP]M)6.0诱导的张力发展。MCI-154、舒马唑、匹莫苯丹和阿迪苯丹以浓度依赖性方式(10(-7)至10(-4)M)增加了离体豚鼠乳头肌的收缩力。效力顺序如下:MCI-154>阿迪苯丹>匹莫苯丹>舒马唑。这些结果表明,对收缩系统的Ca2+增敏作用可能参与了MCI-154、舒马唑、匹莫苯丹和阿迪苯丹的正性肌力作用,且MCI-154在这些药物中效力最强。此外,舒马唑、匹莫苯丹和阿迪苯丹没有增强肌动蛋白和肌球蛋白的相互作用,提示这些药物的作用机制在性质上与MCI-154不同。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验